Cyclopharm (ASX:CYC) entered a clinical research collaboration with Macquarie University and Macquarie University Hospital to evaluate a new treatment approach for patients with severe chronic obstructive pulmonary disease, the Endoscopic Segmental Sealant Ablation (ESSA) study, according to a Thursday Australian bourse filing.

The ESSA procedure is a minimally invasive bronchoscopic treatment targeting damaged parts of the lung at a smaller, segment-by-segment level, seeking to induce segmental lung volume reduction with the instillation of polymer foam.

The study will use artificial intelligence-based lung imaging technology from Thirona, applied to nuclear medicine ventilation-perfusion (V/Q) single-photon emission computed tomography-computed tomography scans generated using Technegas.

The study will recruit 34 patients with severe or very severe chronic obstructive pulmonary disease.